We offer several options to help cover the cost of ACTEMRA® (tocilizumab) for your patients who are uninsured, have been denied covered by their health plans, have concerns about co-pays or are worried about out-of-pocket (OOP) expenses.
Genentech offers the Genentech Rheumatology Co-pay Card Program to help qualified patients with the out-of-pocket costs associated with their prescription.
If privately or publicly insured patients have difficulty paying their ACTEMRA co-pay, co-insurance or other expenses, Genentech Rheumatology Access Solutions can refer them to a co-pay assistance foundation* supporting their disease state.
GATCF was established to help patients with unmet medical needs who are uninsured or rendered uninsured by payer denial and who meet specific financial and medical criteria to receive ACTEMRA free of charge. Learn more
|*||Genentech does not influence or control the operations of these co-pay assistance foundations, but Genentech Rheumatology Access Solutions can assist patients in navigating the process of seeking co-pay assistance by making an appropriate referral based on a patient’s diagnosis and by assisting with the application process. We cannot guarantee co-pay assistance once a patient has been referred by Genentech Rheumatology Access Solutions. The foundations to which we refer patients each have their own criteria for patient eligibility, including financial eligibility.|